Smith & Nephew PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered undervalued, ranking 92/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.16.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Smith & Nephew PLC's Score
Industry at a Glance
Industry Ranking
92 / 208
Overall Ranking
217 / 4582
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
34.157
Target Price
+1.99%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Smith & Nephew PLC Highlights
StrengthsRisks
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.81B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 79.37%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 79.37%.
Undervalued
The company’s latest PE is 29.20, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.77M shares, decreasing 26.97% quarter-over-quarter.
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
Ticker SymbolSNN
CompanySmith & Nephew PLC
CEONath (Deepak S)
Websitehttps://www.smith-nephew.com/
FAQs
What is the current price of Smith & Nephew PLC (SNN)?
The current price of Smith & Nephew PLC (SNN) is 32.845.
What is the symbol of Smith & Nephew PLC?
The ticker symbol of Smith & Nephew PLC is SNN.
What is the 52-week high of Smith & Nephew PLC?
The 52-week high of Smith & Nephew PLC is 38.790.
What is the 52-week low of Smith & Nephew PLC?
The 52-week low of Smith & Nephew PLC is 23.690.
What is the market capitalization of Smith & Nephew PLC?
The market capitalization of Smith & Nephew PLC is 14.39B.
What is the net income of Smith & Nephew PLC?
The net income of Smith & Nephew PLC is 412.00M.
Is Smith & Nephew PLC (SNN) currently rated as Buy, Hold, or Sell?
According to analysts, Smith & Nephew PLC (SNN) has an overall rating of Buy, with a price target of 34.157.
What is the Earnings Per Share (EPS TTM) of Smith & Nephew PLC (SNN)?
The Earnings Per Share (EPS TTM) of Smith & Nephew PLC (SNN) is 1.124.